A day in the life… page 3

Article

A day in the life

Previous page | Next page

Let chaos commence

At this point, I must underline the peculiar character of some of our patients (of course not all, luckily!): loud, aggressive and unpunctual. Since our schedule is very tight (frequent pathologies, many patients, necessity to keep short waiting lists, long and frequent follow-ups), it is imperative to start the day in a rush, otherwise we will very quickly begin to accumulate a delay in appointments, and the patients will start complaining.

We know perfectly well that some patients will have met a traffic jam while others will have missed the bus, so we generally have a schedule of overbooking to compensate for late, ill or absent patients.

Usually a bulk of fluorescein cases, OCT patients, laser photocoagulation cases and routine fundi will stream through our clinic. During the morning we see at least 25 to 30 patients. We do, however, allocate specific days for PDT treatments (usually one day a week), or intraocular injections of anti-angiogenic agents or triamcinolone (twice a week).

Surgical procedures are usually performed twice a week, during which time I bounce in and out of theatre; going from one patient to the next, performing surgery and consultations.

Mornings in the clinic are generally very stressful and it is absolutely essential that the team and I are constantly focused and efficient yet calm. There is never enough time in the day and the last thing that I want to deal with is patients complaining because of the long waiting time. I often hear, 'Doctor, I had an appointment at 10 and it is now 10.30, when will it be my turn?' and 'I want to know exactly how long I must wait.' My patients rarely consider that each person I see is different and the time it takes to treat an extrafoveal small CNV is not the same as that required to perform a retinal panphotocoagulation.

During the morning, most of us do manage a very short coffee break but only one or two of us at a time, so as not to slow down the rate of patient flow.

Previous page | Next page

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.